Edwards Lifesciences (NYSE:EW) Stock Price Up 5.6% – Time to Buy?

Edwards Lifesciences Corporation (NYSE:EW)’s stock price traded up 5.6% on Tuesday . The company traded as high as $80.01 and last traded at $80.1130. 1,287,108 shares were traded during mid-day trading, a decline of 71% from the average session volume of 4,384,525 shares. The stock had previously closed at $75.87.

Analyst Ratings Changes

Several research analysts have recently weighed in on EW shares. Raymond James Financial upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price target for the company in a report on Monday, November 3rd. Canaccord Genuity Group set a $87.00 price target on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research report on Wednesday, December 17th. Piper Sandler reaffirmed an “overweight” rating and issued a $100.00 price objective (up from $98.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Wells Fargo & Company upped their price target on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. Finally, Royal Bank Of Canada boosted their price objective on Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a report on Friday, December 5th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $96.14.

Edwards Lifesciences Price Performance

The stock has a market capitalization of $45.49 billion, a price-to-earnings ratio of 42.84, a P/E/G ratio of 1.99 and a beta of 0.94. The company has a fifty day simple moving average of $83.17 and a 200 day simple moving average of $81.06. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The business had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.54 billion. During the same quarter in the previous year, the business posted $0.59 earnings per share. The business’s revenue was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Equities research analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 11,340 shares of the business’s stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $85.66, for a total transaction of $971,384.40. Following the completion of the sale, the vice president directly owned 31,870 shares of the company’s stock, valued at approximately $2,729,984.20. The trade was a 26.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $85.70, for a total value of $87,328.30. Following the transaction, the vice president directly owned 22,002 shares in the company, valued at approximately $1,885,571.40. The trade was a 4.43% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 43,804 shares of company stock worth $3,699,082 in the last quarter. Insiders own 0.34% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Hedge funds and other institutional investors have recently modified their holdings of the business. Level Four Advisory Services LLC increased its position in shares of Edwards Lifesciences by 3.7% during the 3rd quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company’s stock valued at $257,000 after purchasing an additional 119 shares during the last quarter. Colonial Trust Co SC grew its position in shares of Edwards Lifesciences by 0.4% in the third quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company’s stock valued at $2,504,000 after purchasing an additional 120 shares in the last quarter. Evermay Wealth Management LLC increased its position in shares of Edwards Lifesciences by 4.0% during the fourth quarter. Evermay Wealth Management LLC now owns 3,304 shares of the medical research company’s stock valued at $282,000 after buying an additional 128 shares during the period. Parkside Financial Bank & Trust lifted its stake in Edwards Lifesciences by 9.8% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,455 shares of the medical research company’s stock worth $114,000 after purchasing an additional 130 shares in the last quarter. Finally, Prosperity Consulting Group LLC raised its position in shares of Edwards Lifesciences by 3.2% in the second quarter. Prosperity Consulting Group LLC now owns 4,304 shares of the medical research company’s stock worth $337,000 after buying an additional 132 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.